Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease.

Cardiovascular research - 1 Jul 2020

Prasad Megha, Corban Michel T, Henry Timothy D, Dietz Allan B, Lerman Lilach O, Lerman Amir

Abstract excerpt

CD34+ cells are haematopoietic stem cells used therapeutically in patients undergoing radiation or chemotherapy due to their regenerative potential and ability to restore the haematopoietic system. In animal models, CD34+ cells have been associated with therapeutic angiogenesis in response to ischaemia. Several trials have shown the potential safety and efficacy of CD34+ cell delivery in various cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cardiovascular System

Share to Endothelial Progenitor Cells

Share to Hematopoietic Stem Cell Transplantation

Share to Hematopoietic Stem Cells

Share to Recovery of Function

Share to Regeneration

Source

Identifiers

PMID: 32022845
DOI: 10.1093/cvr/cvaa027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease.PMID 32022845Read ↗

Endothelial progenitor cells in cell-based therapy for cardiovascular disease.Semantic proximity Read ↗

The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemiaSemantic proximity Read ↗

Stem cell‐derived endothelial cells for cardiovascular disease: a therapeutic perspectiveSemantic proximity Read ↗

Regeneration-Associated Cells Improve Recovery from Myocardial Infarction through Enhanced Vasculogenesis, Anti-inflammation, and CardiomyogenesisSemantic proximity Read ↗

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.Semantic proximity Read ↗

CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors.Semantic proximity Read ↗

CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease.Semantic proximity Read ↗

In vitro functional comparison of therapeutically relevant human vasculogenic progenitor cells used for cardiac cell therapy.Semantic proximity Read ↗

Mesenchymal stromal cell therapy in ischemic heart disease.Semantic proximity Read ↗

Endothelial progenitor cells in cardiovascular diseasesSemantic proximity Read ↗

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration.Semantic proximity Read ↗

Identification of Myocardial and Vascular Precursor Cells in Human and Mouse EpicardiumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.